Sign Up Today and Learn More About Pathios Therapeutics Stock
Invest in or calculate the value of your shares in Pathios Therapeutics or other pre-IPO companies through EquityZen's platform.
Pathios Therapeutics Stock (PAHT)
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
About Pathios Therapeutics Stock
Founded
2017
Industries
Software, Artificial Intelligence, Data and Analytics
Pathios Therapeutics Press Mentions
Stay in the know about the latest news on Pathios Therapeutics
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers
prnewswire • Nov 20, 2024
Pathios Therapeutics Appoints Paul G. Higham as Chief Executive Officer
biospace • Jul 09, 2024
Pathios Therapeutics Appoints Paul G. Higham as Chief Executive Officer as Company Prepares to Enter the Clinic
prnewswire • Jul 09, 2024
Bristol Myers backs Pathios as part of $25 million Series B
thepharmaletter • Jul 04, 2024
Bristol Myers backs Pathios as part of $25 million Series B
thepharmaletter • May 20, 2024
Pathios Therapeutics Management
Leadership team at Pathios Therapeutics
Co-Founder
Alan Naylor
Co-Founder
Tom McCarthy
Join now and verify your accreditation status to gain access to:
- Pathios Therapeutics current valuation
- Pathios Therapeutics stock price
- Available deals in Pathios Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Pathios Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Pathios Therapeutics through EquityZen funds. These investments are made available by existing Pathios Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Pathios Therapeutics stock?
Shareholders can sell their Pathios Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
